Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06415435
Other study ID # VIOL-MEL-2022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2023
Est. completion date October 1, 2024

Study information

Verified date May 2024
Source Benev Company, Inc.
Contact Jamie Solorsa
Phone 9494572222
Email jamie@benev.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date October 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Subject must be able to read, understand and sign informed consent form. 2. Healthy females, 19 and older 3. Fitzpatrick I-VI 4. Has melasma 5. Willing to have RF microneedling treatment and able to adhere to treatments, follow up schedule, and post-treatment instructions 6. Willing to have limited sun exposure and use sunscreen on treatment area everyday for duration of study 7. Willing to have photographs taken of treatment area and agree to use of photographs 8. Willing to refrain from using topical corticosteroids, or retinoids 9. Agree to undergo procedure in treatment area during study 10. Females: not pregnant, or lactating and is either post-menopausal, surgically sterilized, or using birth control at least 1 month prior to enrollment 11. Willing to wear sunscreen and apply once daily in morning and every 2 hours Exclusion Criteria: 1. Participation in a clinical trial of another drug, or device administered to the treatment area, within 3 months prior to enrollment or during the study. 2. Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser/light procedures, and those used for general aesthetic correction, neuromodulators, facial peel, lightening creams, or facial surgery. 3. Any fillers within 3 months prior to enrollment or during the study. 4. Use of prescription topicals in the treatment area within one month prior to treatment or use of topical agents one week prior to treatment that may cause facial sensitivity. 5. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including but not limited to, open lacerations or abrasions, hidradenitis, rash, infection, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion). 6. . Pregnant and/or breastfeeding or planning to become pregnant. 7. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or using immunosuppressive medication. 8. Any use of any medication that is known to increase sensitivity to light or hypersensitivity to light exposure according to the Investigator's discretion. 9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone to bruising. 10. If you have a history of squamous cell carcinoma or melanoma in the treatment area, this includes basal cell carcinoma unless: basal cell carcinoma was treated or excised with no evidence of reoccurrence within the past 6 months prior to screening. Squamous cell carcinoma in situ, which has been treated or excised without evidence or reoccurrence within the past 6 months prior to screening. 11. . History of epidermal or dermal disorders (particularly if involving collagen or micro vascularity), including collagen vascular disease or vasculitis disorders. 12. A history or active skin condition that in the opinion of the Investigator may interfere/confound with the treatment. 13. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma. Sponsor: VIOL Version 1, 25APR2022 Protocol: VIOL-MEL-2022 Page 18 of 47 14. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen. 15. Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely to refrain from tanning during the study. 16. Excessive facial hair in the area to be treated (beards, sideburns, and/or mustache,) that would interfere with diagnosis, assessment, and treatment. 17. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study, including excessive alcohol or drug abuses, or a condition that would compromise the subject's ability to comply with the study requirements. 18. To reduce potential effects of hormonal changes in melasma, a 6-month washout period is required for female subjects who have recently stopped or started contraceptive use, have recently delivered an infant, or have stopped breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Radiofrequency Microneedling
Sylfirm X radiofrequency microneedling device

Locations

Country Name City State
United States Dermatology, Laser & Vein Specialists of the Carolinas, PLLC Charlotte North Carolina
United States Refresh Dermatology Houston Texas
United States Scripps Health La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
Benev Company, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of photos accurately identified as post-treatment photo vs. baseline by a blind investigator from 0-100% Success criteria: 80% accuracy in identifying the baseline photo from post-treatment photos. 28 days
Secondary Change in Modified Melasma Area and Severity Index (mMASI) scale measured by investigator (range 0-24), a lower score indicating clearer skin. The Modified Melasma Area and Severity Index scale will be utilized to grade melasma severity. Success criteria: improvement by 1 point, ie. at least 1 point lower than baseline. 28 days
Secondary Percentage of subjects with an increase in satisfaction level assessed from Melasma Quality of Life questionnaire (MELQoL) after treatment compared to baseline MELQoL is a questionnaire on a scale of 0 to 7 on how the patients feel about skin appearance, skin condition, embarrassment about skin condition, etc. 28 days
Secondary Statistical improvement of investigator Global Aesthetic Improvement Scale (GAIS) Success criteria: On a scale of -1 (skin got worse) to 3 (skin very much improved), incidence of subject improvement was statistically significant. 28 days
See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT05656833 - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Terminated NCT03415685 - Lutronic PicoPlus Exploratory Clinical Trial N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3